Provided by Tiger Trade Technology Pte. Ltd.

Verastem

6.86
-0.0300-0.44%
Post-market: 6.79-0.0700-1.02%19:30 EDT
Volume:1.17M
Turnover:8.00M
Market Cap:621.27M
PE:-2.84
High:6.96
Open:6.90
Low:6.62
Close:6.89
52wk High:11.25
52wk Low:3.43
Shares:90.56M
Float Shares:70.57M
Volume Ratio:0.54
T/O Rate:1.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4143
EPS(LYR):-3.0223
ROE:-471.16%
ROA:-49.59%
PB:12.43
PE(LYR):-2.27

Loading ...

Mizuho Adjusts Price Target on Verastem to $13 From $14, Keeps Outperform Rating

MT Newswires Live
·
Aug 11

Verastem price target lowered to $13 from $14 at Mizuho

TIPRANKS
·
Aug 11

Verastem is Maintained at Buy by Guggenheim

Dow Jones
·
Aug 08

Verastem - Enters Amendment No. 3 to Note Purchase Agreement on August 6, 2026 - SEC Filing

THOMSON REUTERS
·
Aug 07

Verastem - Establishes Initial Notes of $75 Mln and Revenue Notes up to $75 Mln - SEC Filing

THOMSON REUTERS
·
Aug 07

Verastem Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 07

Verastem Q2 Revenue Jumps on New Product Sales and Milestone

Reuters
·
Aug 07

Verastem Q2 FY26 GAAP Net Loss Widens to $34.67 Million; Revenue Rises to $40.08 Million

Reuters
·
Aug 07

Verastem Q2 Adj. EPS $(0.35) Beats $(0.43) Estimate, Sales $25.078M Beat $23.093M Estimate

Benzinga Earnings
·
Aug 07

Verastem Q2 Operating Expenses USD 72.788 Million

Reuters
·
Aug 07

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

THOMSON REUTERS
·
Aug 07

Verastem’s TARGET-D 202 Trial Puts Fresh Focus on KRAS G12D Lung Cancer

TIPRANKS
·
Jul 31

Verastem Oncology Doses First Patient in Target-D 203 Phase 2 Registration-Directed Trial of Vs-7375 Oral Kras G12d (on/off) Inhibitor for Kras G12d-Mutated Metastatic Colorectal Cancer

THOMSON REUTERS
·
Jul 29

Verastem - Initiates Treatment in All Three Target-D Phase 2 Trials

THOMSON REUTERS
·
Jul 29

Press Release: Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026

Dow Jones
·
Jul 23

Verastem Oncology to Report Q2 2026 Financial Results in Conference Call

Reuters
·
Jul 23

Verastem doses first patient in TARGET-D 202 Phase 2 trial

TIPRANKS
·
Jul 23

Verastem Oncology Doses First Patient in Target-d 202 Phase 2 Registration-directed Trial of Vs-7375 for Kras G12d-mutated Advanced Non-small Cell Lung Cancer

THOMSON REUTERS
·
Jul 23

These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why

Benzinga_recent_news
·
Jul 22

Verastem’s KRAS G12D Trial Targets a New Niche in Colorectal Cancer

TIPRANKS
·
Jul 18